Urgent.News

What's breaking now, across thousands of outlets.

Health & Medicine

Surrozen receives FDA clearance for SZN-8141 IND application

Surrozen receives FDA clearance for SZN-8141 IND application

Surrozen, Inc., a company listed on NASDAQ under the ticker SRZN, has announced that the U.S. Food and Drug Administration has granted its Investigational New Drug application for SZN-8141 full clearance. SZN-8141 is a novel drug being developed as an intravitreal injection to treat diabetic macular edema, a condition characterized by swelling of the macula, the central part of the retina responsible for sharp, detailed vision.

The company anticipates enrolling its first patient in the DUET clinical trial, a Phase 1b/2a study, by the end of 2026. The FDA approval marks the completion of the second major milestone in Surrozen's March 2025 private placement, a two-tranche fundraising round. The successful second tranche is expected to generate around $95.1 million in gross proceeds for the company, after accounting for fees and expenses.

The funds raised will be used to support the ongoing clinical trials and further development of SZN-8141. The DUET study is a two-phase clinical trial, with the first phase being an open-label single-dose portion, and the second phase a randomized, double-masked dose-expansion study. The Phase 2a portion aims to compare the efficacy of SZN-8141 against Vabysmo, another intravitreal drug, in approximately 60 patients with diabetic macular edema who have not yet received treatment.

The initial results from the DUET study are anticipated in the second half of 2027. Surrozen plans to expand its research to include neovascular age-related macular degeneration and other retinal vascular diseases once the DUET study is complete. Following the successful second tranche, Surrozen intends to file a new registration statement on Form S-3 with the Securities and Exchange Commission to facilitate the resale of shares issued during the fundraising round.

Written by urgent.news from Investing.com's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.

Read the original at investing.com →

More in Health & Medicine

More from Friday 2 October →